Abstract
To evaluate smooth muscle differentiation, myogenic markers [desmin, alpha-smooth muscle actin (SMA), and muscle-specific actin (HHF35)] have been widely used. Calponin and h-caldesmon, which are cytoskeleton-associated actin-binding proteins, have been reported to be more specific myogenic markers, especially since myofibroblasts express a small amount of h-caldesmon. Atypical fibroxanthoma (AFX) occurs in the sun-exposed skin of the elderly and follows a benign clinical course. Histologically, AFX, which is a pleomorphic spindle cell tumor and considered to be a superficial variant of malignant fibrous histiocytoma, also mimics leiomyosarcoma. AFX has been thought to differentiate along pathways with fibrohistiocytic and myofibroblastic phenotypes. AFX (n=10), superficial leiomyosarcoma (S-LMS) (n=17) and benign fibrous histiocytoma (BFH) (n=17) were analyzed for myofibroblastic and smooth muscle differentiation immunohistochemically from the viewpoint of comparison. AFX and BFH showed immunoreactivities respectively for calponin (3/10, 11/17), desmin (3/10, 1/17), SMA (3/10, 13/17), and HHF35 (1/10, 5/17), but failed to express h-caldesmon (0/10, 0/17). S-LMS had a high immunoreactive rate of calponin (17/17), desmin (13/17), SMA (16/17), and HHF35 (16/17), while also expressing caldesmon (11/17). The results reveal that AFX and BFH have immunoreactivities for several myogenic markers, with myofibroblastic differentiation (calponin: ±, h-caldesmon: -), but without the smooth muscle differentiation seen in S-LMS (calponin:+, h-caldesmon: ±). In addition, calponin and h-caldesmon are considered to be useful markers for distinguishing AFX from S-LMS.
| Original language | English |
|---|---|
| Pages (from-to) | 404-409 |
| Number of pages | 6 |
| Journal | Virchows Archiv |
| Volume | 440 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 27 2002 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pathology and Forensic Medicine
- Molecular Biology
- Cell Biology
Cite this
Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma. / Sakamoto, A.; Oda, Yoshinao; Yamamoto, Hidetaka; Oshiro, Y.; Miyajima, K.; Itakura, E.; Tamiya, S.; Honda, Y.; Ishihara, A.; Iwamoto, Y.; Tsuneyoshi, M.
In: Virchows Archiv, Vol. 440, No. 4, 27.04.2002, p. 404-409.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma
AU - Sakamoto, A.
AU - Oda, Yoshinao
AU - Yamamoto, Hidetaka
AU - Oshiro, Y.
AU - Miyajima, K.
AU - Itakura, E.
AU - Tamiya, S.
AU - Honda, Y.
AU - Ishihara, A.
AU - Iwamoto, Y.
AU - Tsuneyoshi, M.
PY - 2002/4/27
Y1 - 2002/4/27
N2 - To evaluate smooth muscle differentiation, myogenic markers [desmin, alpha-smooth muscle actin (SMA), and muscle-specific actin (HHF35)] have been widely used. Calponin and h-caldesmon, which are cytoskeleton-associated actin-binding proteins, have been reported to be more specific myogenic markers, especially since myofibroblasts express a small amount of h-caldesmon. Atypical fibroxanthoma (AFX) occurs in the sun-exposed skin of the elderly and follows a benign clinical course. Histologically, AFX, which is a pleomorphic spindle cell tumor and considered to be a superficial variant of malignant fibrous histiocytoma, also mimics leiomyosarcoma. AFX has been thought to differentiate along pathways with fibrohistiocytic and myofibroblastic phenotypes. AFX (n=10), superficial leiomyosarcoma (S-LMS) (n=17) and benign fibrous histiocytoma (BFH) (n=17) were analyzed for myofibroblastic and smooth muscle differentiation immunohistochemically from the viewpoint of comparison. AFX and BFH showed immunoreactivities respectively for calponin (3/10, 11/17), desmin (3/10, 1/17), SMA (3/10, 13/17), and HHF35 (1/10, 5/17), but failed to express h-caldesmon (0/10, 0/17). S-LMS had a high immunoreactive rate of calponin (17/17), desmin (13/17), SMA (16/17), and HHF35 (16/17), while also expressing caldesmon (11/17). The results reveal that AFX and BFH have immunoreactivities for several myogenic markers, with myofibroblastic differentiation (calponin: ±, h-caldesmon: -), but without the smooth muscle differentiation seen in S-LMS (calponin:+, h-caldesmon: ±). In addition, calponin and h-caldesmon are considered to be useful markers for distinguishing AFX from S-LMS.
AB - To evaluate smooth muscle differentiation, myogenic markers [desmin, alpha-smooth muscle actin (SMA), and muscle-specific actin (HHF35)] have been widely used. Calponin and h-caldesmon, which are cytoskeleton-associated actin-binding proteins, have been reported to be more specific myogenic markers, especially since myofibroblasts express a small amount of h-caldesmon. Atypical fibroxanthoma (AFX) occurs in the sun-exposed skin of the elderly and follows a benign clinical course. Histologically, AFX, which is a pleomorphic spindle cell tumor and considered to be a superficial variant of malignant fibrous histiocytoma, also mimics leiomyosarcoma. AFX has been thought to differentiate along pathways with fibrohistiocytic and myofibroblastic phenotypes. AFX (n=10), superficial leiomyosarcoma (S-LMS) (n=17) and benign fibrous histiocytoma (BFH) (n=17) were analyzed for myofibroblastic and smooth muscle differentiation immunohistochemically from the viewpoint of comparison. AFX and BFH showed immunoreactivities respectively for calponin (3/10, 11/17), desmin (3/10, 1/17), SMA (3/10, 13/17), and HHF35 (1/10, 5/17), but failed to express h-caldesmon (0/10, 0/17). S-LMS had a high immunoreactive rate of calponin (17/17), desmin (13/17), SMA (16/17), and HHF35 (16/17), while also expressing caldesmon (11/17). The results reveal that AFX and BFH have immunoreactivities for several myogenic markers, with myofibroblastic differentiation (calponin: ±, h-caldesmon: -), but without the smooth muscle differentiation seen in S-LMS (calponin:+, h-caldesmon: ±). In addition, calponin and h-caldesmon are considered to be useful markers for distinguishing AFX from S-LMS.
UR - http://www.scopus.com/inward/record.url?scp=0036216633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036216633&partnerID=8YFLogxK
U2 - 10.1007/s004280100521
DO - 10.1007/s004280100521
M3 - Article
VL - 440
SP - 404
EP - 409
JO - Virchows Archiv
JF - Virchows Archiv
SN - 0945-6317
IS - 4
ER -